arrow
H

Helena Linardou

Metropolitan Hospital
H指数:37
被引数:8,717

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the KRYSTAL-12 study results: adagrasib for non−small cell lung cancer with KRASG12C mutations

KRYSAL-12研究的通俗结果摘要:针对KRASG12C突变的非小细胞肺癌的adagrasib治疗

2026-09-160
OAAI
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib 与多西他赛在 KRASG12C 突变非小细胞肺癌中的比较(KRYSTAL-12):一项随机、开放标签、III 期临床试验

2025-08-070
PRE
Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.

插入式阿维鲁唑胺联合铂类为基础的化疗在广泛期小细胞肺癌患者中的应用(PAVE):一项多中心Hellenic Cooperative Oncology Group II期研究的最终结果、免疫表型分析和生物标志物分析。

2025-07-250
OAAI
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer

分子肿瘤委员会:国际肺癌研究协会的共识声明

2025-07-070
PRE
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–PD-(L)1 Plus Platinum Chemotherapy

LEAP-008: Lenvatinib联合Pembrolizumab治疗既往接受过抗PD-(L)1联合铂类化疗后进展的转移性NSCLC

2025-06-030
PREAI
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study
2025-01-090
PRE
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
2024-10-211
OAAI
Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis

晚期非小细胞肺癌患者数字支持的临床和分子研究: snf-climedin,一项前瞻性随机希腊肿瘤协作组 (HeCOG) 研究: 中期分析

2023-10-011
OAAI
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
2023-06-017
PRE
Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Sotorasib与多西他赛治疗KRASG12C突变的非小细胞肺癌: 一项随机,开放标签,3期试验

LANCET
IF88.5
2023-03-01219
OAAI
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

一线nivolumab联合ipilimumab治疗转移性非小细胞肺癌,包括ECOG表现状态2和其他特殊人群的患者: CheckMate 817

2023-02-0133
OAAI
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

精确肿瘤学时代EGFR外显子20突变NSCLC患者的分子流行病学和治疗模式: 欧洲异国注册中心

2023-01-0114
OA